Quantifying emerging drugs for very rare conditions

Kathryn Miles; Claire Packer; Andrew Stevens

doi:10.1093/qjmed/hcm021

Quantifying emerging drugs for very rare conditions

Kathryn Miles, Claire Packer, Andrew Stevens

Research output: Contribution to journal › Article

10 Citations (Scopus)

Abstract

BACKGROUND: EU legislation is encouraging pharmaceutical companies to develop drugs for rare conditions, but their often high cost, and potential for long-term administration has led to debate about their affordability and cost-effectiveness. AIM: To investigate how many drugs are in development for very rare conditions. METHODS: We defined very rare conditions as having a prevalence of

Original language	English
Pages (from-to)	291-295
Number of pages	5
Journal	QJM
Volume	100
Early online date	27 Mar 2007
DOIs	https://doi.org/10.1093/qjmed/hcm021
Publication status	Published - 27 Mar 2007

Access to Document

10.1093/qjmed/hcm021

Cite this

@article{ff62023dad664a48a66490b2437ab4a5,

title = "Quantifying emerging drugs for very rare conditions",

abstract = "BACKGROUND: EU legislation is encouraging pharmaceutical companies to develop drugs for rare conditions, but their often high cost, and potential for long-term administration has led to debate about their affordability and cost-effectiveness. AIM: To investigate how many drugs are in development for very rare conditions. METHODS: We defined very rare conditions as having a prevalence of ",

author = "Kathryn Miles and Claire Packer and Andrew Stevens",

year = "2007",

month = mar,

day = "27",

doi = "10.1093/qjmed/hcm021",

language = "English",

volume = "100",

pages = "291--295",

journal = "QJM",

issn = "1460-2393",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Quantifying emerging drugs for very rare conditions

AU - Miles, Kathryn

AU - Packer, Claire

AU - Stevens, Andrew

PY - 2007/3/27

Y1 - 2007/3/27

N2 - BACKGROUND: EU legislation is encouraging pharmaceutical companies to develop drugs for rare conditions, but their often high cost, and potential for long-term administration has led to debate about their affordability and cost-effectiveness. AIM: To investigate how many drugs are in development for very rare conditions. METHODS: We defined very rare conditions as having a prevalence of

AB - BACKGROUND: EU legislation is encouraging pharmaceutical companies to develop drugs for rare conditions, but their often high cost, and potential for long-term administration has led to debate about their affordability and cost-effectiveness. AIM: To investigate how many drugs are in development for very rare conditions. METHODS: We defined very rare conditions as having a prevalence of

U2 - 10.1093/qjmed/hcm021

DO - 10.1093/qjmed/hcm021

M3 - Article

C2 - 17456610

SN - 1460-2393

VL - 100

SP - 291

EP - 295

JO - QJM

JF - QJM

ER -

Quantifying emerging drugs for very rare conditions

Abstract

Access to Document

Fingerprint

Cite this